title: Globe size and bevacizumab treatment in retinopathy of prematurity: should we adjust the dose?
authors.affiliation: Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
authors.forename: A J
authors.initials: AJ
authors.lastname: Connor
authors.affiliation: Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
authors.forename: A
authors.initials: A
authors.lastname: Shafiq
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D058452:Axial Length, Eye / Q000378:metabolism / Q000473:pathology*; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D058449:Intravitreal Injections; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000378:metabolism; D012189:Retrospective Studies; D014018:Tissue Distribution; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab